Altered expression pattern of topoisomerase IIα in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy

Neoplasia

Volumn 8, Issue 1, 2006, Pages 38-45

  Chekerov, Radoslav ^a   Klaman, Irina ^a   Zafrakas, Menelaos ^b   Könsgen, Dominique ^a   Mustea, Alexander ^a   Petschke, Beate ^a   Lichtenegger, Werner ^a   Sehouli, Jalid ^a   Dahl, Edgar ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Chemotherapy resistance; Ovarian cancer; RNA in situ hybridization; TOP2A; Tumor stromal cells

Indexed keywords

CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); MESSENGER RNA; PACLITAXEL; PLATINUM;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LASER MICRODISSECTION; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA CELL;

EID: 33646409018     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.05580     Document Type: Article

References (48)

1. Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HY, Sideri M, and Pecorelli S (2001). Carcinoma of the ovary. J Epidemiol Biostat 6, 107-138.
2. Lichtenegger W, Sehouli J, Buchmann E, Karajanev C, and Weidemann H (1998). Operative results after primary and secondary debulking-operations in advanced ovarian cancer (AOC). J Obstet Gynaecol Res 24, 447-451.
3. Conte PF, Gadducci A, and Cianci C (2001). Second-line treatment and consolidation therapies in advanced ovarian cancer. Int J Gynecol Cancer 11, 52-56.
4. Wang JC (2002). Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 3, 430-440.
5. Lang AJ, Mirski SE, Cummings HJ, Yu Q, Gerlach JH, and Cole SP (1998). Structural organization of the human TOP2A and TOP2B genes. Gene 221, 255-266.
6. Seiden MV, Ng SW, Supko JG, Ryan DP, Clark JW, Lynch T, Huang KC, Kwiatkowski D, Skarin A, Eder JP Jr (2002). A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors. Clin Cancer Res 8, 691-697.
7. Burden DA and Osheroff N (1998). Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim Biophys Acta 1400, 139-154.
8. Sehouli J, Horstkamp B, Schonborn I, Kettner H, and Lichtenegger W (1998). Prospective, randomized phase II trial: carboplatin and oral etoposide versus carboplatin and cyclophosphamide in the first-line treatment of ovarian cancer 17th International Cancer Congress, 1259-1263.
9. Oskay-Özcelik G, Sehouli J, Sommer H, Klare P, Stauch M, Zeimet A, Paulenz A, Renziehausen K, Keil E, and Lichtenegger W (2004). Randomized phase III trial: topotecan vs topotecan/etoposide vs topotecan/gemcitabine as second-line treatment for patients with relapsed ovarian cancer. Proc ASCO 2004, 5139 (Abstract).
10. Vermorken JB, Harper PG, and Buyse M (1999). The role of anthracyclines in epithelial ovarian cancer. Ann Oncol 10 (Suppl 1), 43-50.
11. Dingemans AM, Pinedo HM, and Giaccone G (1998). Clinical resistance to topoisomerase-targeted drugs. Biochim Biophys Acta 1400, 275-288.
12. Kohn KW, Pommier Y, Kerrigan D, Markovits J, and Covey JM (1987). Topoisomerase II as a target of anticancer drug action in mammalian cells. NCI Monogr 4, 61-71.
13. Larsen AK and Skladanowski A (1998). Cellular resistance to topoisomerase-targeted drugs: from drug uptake to cell death. Biochim Biophys Acta 1400, 257-274.
14. Chung TD, Drake FH, Tan KB, Per SR, Crooke ST, and Mirabelli CK (1989). Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isoenzymes. Proc Natl Acad Sci USA 86, 9431-9435.
15. Schneider E and Earnshaw WC (1986). Topoisomerase II: a specific marker for cell proliferation. J Cell Biol 103, 2569-2581.
16. Hicks DG, Yoder BJ, Pettay J, Swain E, Tarr S, Hartke M, Skacel M, Crowe JP, Budd GT, and Tubbs RR (2005). The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study. Hum Pathol 36, 348-356.
17. Jacobson KK, Morrison LE, Henderson BT, Blondin BA, Wilber KA, Legator MS, O'Hare A, Van Stedum SC, Proffitt JH, Seelig SA, et al. (2004). Gene copy mapping of the ERBB2/TOP2A region in breast cancer. Genes Chromosomes Cancer 40, 19-31.
18. Varis A, Zaika A, Puolakkainen P, Nagy B, Madrigal I, Kokkola A, Vayrynen A, Karkkainen P, Moskaluk C, El-Rifai W, et al. (2004). Coamplified and overexpressed genes at ERBB2 locus in gastric cancer. Int J Cancer 109, 548-553.
19. Simon R, Atefy R, Wagner U, Forster T, Fijan A, Bruderer J, Wilber K, Mihatsch MJ, Gasser T, and Sauter G (2003). HER-2 and TOP2A coamplification in urinary bladder cancer. Int J Cancer 107, 764-772.
20. Mano MS, Awada A, Di Leo A, Durbecq V, Paesmans M, Cardoso F, Larsimont D, and Piccart M (2004). Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma. Gynecol Oncol 92, 887-895.
21. Tanner B, Pilch H, Schaffer U, Franzen A, Seufert R, and Hengstler JG (2002). Die Expression von c-erbB-2 und topoisomerase IIα in Relation zur Zytostatikaresistenz beim Ovarialkarzinom. Zentralbl Gynakol 124, 176-183.
22. Hengstler JG, Lange J, Kett A, Dornhofer N, Meinert R, Arand M, Knapstein PG, Becker R, Oesch F, and Tanner B (1999). Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer. Cancer Res 59, 3206-3214.
23. Sandri MI, Isaacs RJ, Ongkeko WM, Harris AL, Hickson ID, Broggini M, and Vikhanskaya F (1996). p53 regulates the minimal promoter of the human topoisomerase IIalpha gene. Nucleic Acids Res 24, 4464-4470.
24. Cornarotti M, Capranico G, Bohm S, Oriana S, Spatti GB, Mariani L, Ballabio G, and Zunino F (1996). Gene expression of DNA topoisomerases I, II alpha and II beta and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Int J Cancer 67, 479-484.
25. Yasui K, Mihara S, Zhao C, Okamoto H, Saito-Ohara F, Tomida A, Funato T, Yokomizo A, Naito S, Imoto I, et al. (2004). Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res 64, 1403-1410.
26. Koshiyama M, Fujii H, Kinezaki M, Morita Y, Nanno H, and Yoshida M (2001). Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas. Anticancer Res 21, 2925-2932.
27. van der Zee AG, HollemaH, de Jong S, Boonstra H, GouwA, Willemse PH, Zijlstra JG, and de Vries EG (1991). P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res 51, 5915-5920.
28. Kolfschoten GM, Hulscher TM, Pinedo HM, and Boven E (2000). Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts. Br J Cancer 83, 921-927.
29. Holden JA, Rahn MP, Jolles CJ, Vorobyev SV, and Bronstein IB (1997). Immunohistochemical detection of DNA topoisomerase I in formalin fixed, paraffin wax embedded normal tissues and in ovarian carcinomas. Mol Pathol 50, 247-253.
30. Sorbe B, Frankendal B, and Veress B (1982). Importance of histologic grading in the prognosis of epithelial ovarian carcinoma. Obstet Gynecol 59, 576-582.
31. Sehouli J, Lichtenegger W, Hauptmann S, and Dietl M (2002). Therapie von Borderline - Tumoren des Ovars. Frauenarzt 43, 1201-1207.
32. Fend F, Kremer M, and Quintanilla-Martinez L (2000). Laser capture microdissection: methodical aspects and applications with emphasis on immuno-laser capture microdissection. Pathobiology 68, 209-214.
33. Fend F and Raffeld M (2000). Laser capture microdissection in pathology. J Clin Pathol 53, 666-672.
34. Chomczynski P and Sacchi N (1987). Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162, 156-159.
35. Fink L, Seeger W, Ermert L, Hanze J, Stahl U, Grimminger F, Kummer W, and Bohle RM (1998). Real-time quantitative RT-PCR after laser-assisted cell picking. Nat Med 4, 1329-1333.
36. Remmele W and Stegner HE (1987). Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8, 138-140.
37. Kellner U, Heidebrecht HJ, Rudolph P, Biersack H, Buck F, Dakowski T, Wacker HH, Domanowski M, Seidel A, Westergaard O, et al. (1997). Detection of human topoisomerase II alpha in cell lines and tissues: characterization of five novel monoclonal antibodies. J Histochem Cytochem 45, 251-263.
38. Matsumoto Y, Tamiya T, and Nagao S (2005). Resistance to topoisomerase II inhibitors in human glioma cell lines overexpressing multidrug resistant associated protein (MRP) 2. J Med Invest 52, 41-48.
39. Licitra EJ, Vyas V, Nelson K, Musanti R, Beers S, Thomas C, Poplin E, Smith S, Lin Y, Schaaf LJ, et al. (2003). Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy. Clin Cancer Res 9, 1673-1679.
40. Krtolica A and Campisi J (2002). Cancer and aging: a model for the cancer promoting effects of the aging stroma. Int J Biochem Cell Biol 34, 1401-1414.
41. van den Hooff A (1988). Stromal involvement in malignant growth. Adv Cancer Res 50, 159-196.
42. Tlsty TD and Hein PW (2001). Know thy neighbor: stromal cells can contribute oncogenic signals. Curr Opin Genet Dev 11, 54-59.
43. Chrenek MA, Wong P, and Weaver VM (2001). Tumour-stromal interactions. Integrins and cell adhesions as modulators of mammary cell survival and transformation. Breast Cancer Res 3, 224-229.
44. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, and Cunha GR (1999). Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 59, 5002-5011.
45. Sternlicht MD, Lochter A, Sympson CJ, Huey B, Rougier JP, Gray JW, Pinkel D, Bissell MJ, and Werb Z (1999). The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 98, 137-146.
46. Skobe M and Fusenig NE (1998). Tumorigenic conversion of immortal human keratinocytes through stromal cell activation. Proc Natl Acad Sci USA 95, 1050-1055.
47. Barcellos-Hoff MH and Ravani SA (2000). Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res 60, 1254-1260.
48. Bingham C, Roberts D, and Hamilton TC (2001). The role of molecular biology in understanding ovarian cancer initiation and progression. Int J Gynecol Cancer 11 (Suppl 1), 7-11.